Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Maria Shtessel

Allergy & Immunology New York, NY Medical Doctor

NPI 1720422819 CMS profile 5700029

5 E 98Th St, --, New York, NY 10029

Open in the dashboard

General payments

$68

3 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Maria Shtessel of New York, NY is reported in the CMS Open Payments database as having received $68 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 8th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $24 1
2019 General $43 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maria Shtessel
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Maria Shtessel were reported at $0. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Maria Shtessel Allergy & Immunology median Middle half National median
2019 $43 $378 $115–$1,178 $163
2020 $24 $303 $75–$1,581 $114
2021 $0 $407 $122–$1,475 $132
2022 $0 $357 $120–$1,340 $149
2023 $0 $445 $124–$1,536 $160
2024 $0 $541 $129–$1,763 $164
2025 $0 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. AstraZeneca Pharmaceuticals LP $68 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $68 3 payments
Products named General payments · program years 2019–2020
  1. FASENRA $68 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

239

Median for Allergy/ Immunology: 449

Drug cost

$114,637

Median for Allergy/ Immunology: $169,700

Branded share of claims

18.8%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 17 $61,076
Xolair Omalizumab Brand 13 $35,429
Epinephrine Generic 40 $8,881
Breo Ellipta Fluticasone/Vilanterol Brand 15 $7,955
Ipratropium Bromide Generic 27 $572
Azelastine Hcl Generic 73 $419
Fluticasone Propionate Generic 41 $275
Montelukast Sodium Generic 13 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$18,993

Medicare's payments for the services billed

Medicare patients

107

Average age 70

Services billed

807

82 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 50%
Diabetes 36%
Osteoporosis 23%
Ischemic heart disease 22%
Depression 21%
Cancer 16%
Chronic kidney disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record